サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1421610

骨髄増殖性障害治療市場、シェア、規模、動向、産業分析レポート：タイプ別、治療別、最終用途別、地域別、セグメント別予測、2023年～2032年

Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
骨髄増殖性障害治療市場、シェア、規模、動向、産業分析レポート：タイプ別、治療別、最終用途別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年11月23日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Researchの最新調査によると、世界の骨髄増殖性障害治療市場規模は2032年までに131億3,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

新薬の利用可能性が高まり、潜在的な治療法の強力なパイプラインが存在します。このため、将来はより効果的な治療法が登場するとの楽観的な見方が生まれ、市場への関心と投資を促進しています。骨髄増殖性疾患の罹患率の上昇は、ライフスタイルの変化と高齢化に起因しています。これらの要因により、これらの疾患を発症するリスクのある人の数が増加し、治療に対する需要が高まっています。

さらに、骨髄増殖性疾患に対する一般市民の意識も高まっています。こうした意識の高まりが早期診断・早期治療につながり、同市場における治療薬需要をさらに押し上げています。さらに、骨髄増殖性障害の治療薬として一般的に使用されているJakafiに不耐容の患者に対する治療オプションの開発は、注目すべき動向です。このセカンドライン治療法は、Jakafiが効きにくい患者のニーズに対応するもので、市場の潜在的な患者基盤を拡大するものです。

慢性骨髄増殖性疾患（MPD）は、骨髄と末梢血中のある種の血液細胞の異常増殖を特徴とする、まれな血液悪性腫瘍の一群です。これらの疾患は主に、赤血球、顆粒球（白血球の一種）、血小板を含む骨髄球系とその前駆細胞に影響を及ぼします。これらの疾患は、フィラデルフィア染色体の有無によってさらに分類されます。フィラデルフィア染色体は、9番染色体と22番染色体間の転座（遺伝物質の交換）に起因する特異的な遺伝子異常です。フィラデルフィア染色体の存在はCMLの特徴です。

慢性骨髄増殖性障害は複雑な疾患であり、医療専門家による慎重な診断と管理が必要です。治療の選択肢としては、血球数をコントロールし、症状を管理し、合併症のリスクを軽減するための薬物療法があります。場合によっては、根治的な治療法として幹細胞移植が考慮されることもあります。

骨髄増殖性疾患（MPN）の発症率が東アジア諸国と比較して北米と西欧で高いのは、遺伝的素因、生活習慣、環境要因の違いなど様々な要因によるものと考えられます。MPN患者の多くは60歳以降に診断されるが、これらの疾患は年齢に関係なく発症する可能性があります。米国は、対象人口の多さ、先進的な医療インフラ、研究開発への多額の投資により、MPNに対する革新的な治療法の利用が可能であることから、MPN治療薬の最も有力な市場となる見込みです。

骨髄増殖性疾患治療市場レポート・ハイライト

  • 骨髄線維症分野は、症例数の増加と治療法の有効性を高めるための研究開発努力の増加により、最大のシェアを占めました。
  • 化学療法分野は、食生活の変化や多忙なライフスタイルに起因するがん症例の急増により市場を牽引
  • 北米は、医療インフラが発達していること、研究開発のための産学連携が盛んであることから、最大のシェアを獲得しました。
  • 主要参入企業は、Novartis、Bristol-Myers、Incyte Corp、Takeda Pharmaceutical、Viatris、AbbVie、Teva Pharmaceuticalsなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の骨髄増殖性疾患治療市場別洞察

  • 骨髄増殖性疾患治療市場-最終用途のスナップショット
  • 骨髄増殖性疾患治療市場力学
    • 促進要因と機会
      • 効果的な治療に対する需要の高まり
      • 研究開発と分子理解の進歩
    • 抑制要因と課題
      • 限られた治療選択肢
  • PESTEL分析
  • 骨髄増殖性疾患治療市場の最終使用動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の骨髄増殖性障害治療市場、タイプ別

  • 主要調査結果
  • イントロダクション
  • 真性赤血球増加症
  • 本態性血小板血症
  • 骨髄線維症
  • その他

第6章 世界の骨髄増殖性疾患治療市場、治療別

  • 主要調査結果
  • イントロダクション
  • 化学療法
  • 免疫療法
  • 幹細胞移植
  • その他

第7章 世界の骨髄増殖性障害治療市場、最終用途別

  • 主要調査結果
  • イントロダクション
  • 病院
  • 専門クリニック
  • その他

第8章 世界の骨髄増殖性障害治療市場、地域別

  • 主要調査結果
  • イントロダクション
    • 骨髄増殖性疾患治療市場評価、地域、2019～2032年
  • 骨髄増殖性疾患治療市場-北米
    • 北米：骨髄増殖性疾患治療市場、タイプ別、2019～2032年
    • 北米：骨髄増殖性疾患治療市場、最終用途別、2019～2032年
    • 北米：骨髄増殖性疾患治療市場、治療別、2019～2032年
    • 骨髄増殖性疾患治療市場-米国
    • 骨髄増殖性障害治療市場-カナダ
  • 骨髄増殖性疾患治療市場-欧州
    • 欧州：骨髄増殖性疾患治療市場、タイプ別、2019～2032年
    • 欧州：骨髄増殖性疾患治療市場、最終用途別、2019～2032年
    • 欧州：骨髄増殖性疾患治療市場、治療別、2019～2032年
    • 骨髄増殖性疾患治療市場-英国
    • 骨髄増殖性疾患治療市場-フランス
    • 骨髄増殖性疾患治療市場-ドイツ
    • 骨髄増殖性疾患治療市場-イタリア
    • 骨髄増殖性疾患治療市場-スペイン
    • 骨髄増殖性疾患治療市場-オランダ
    • 骨髄増殖性疾患治療市場-ロシア
  • 骨髄増殖性疾患治療市場-アジア太平洋
    • アジア太平洋：骨髄増殖性疾患治療市場、タイプ別、2019～2032年
    • アジア太平洋：骨髄増殖性疾患治療市場、最終用途別、2019～2032年
    • アジア太平洋：骨髄増殖性疾患治療市場、治療別、2019～2032年
    • 骨髄増殖性疾患治療市場-中国
    • 骨髄増殖性疾患治療市場-インド
    • 骨髄増殖性疾患治療市場-マレーシア
    • 骨髄増殖性疾患治療市場-日本
    • 骨髄増殖性疾患治療市場-インドネシア
    • 骨髄増殖性疾患治療市場-韓国
  • 骨髄増殖性疾患治療市場-中東・アフリカ
    • 中東・アフリカ：骨髄増殖性疾患治療市場、タイプ別、2019～2032年
    • 中東・アフリカ：骨髄増殖性疾患治療市場、最終用途別、2019～2032年
    • 中東・アフリカ：骨髄増殖性疾患治療市場、治療別、2019～2032年
    • 骨髄増殖性疾患治療市場-サウジアラビア
    • 骨髄増殖性疾患治療市場-アラブ首長国連邦
    • 骨髄増殖性疾患治療市場-イスラエル
    • 骨髄増殖性疾患治療市場-南アフリカ
  • 骨髄増殖性疾患治療市場-ラテンアメリカ
    • ラテンアメリカ：骨髄増殖性疾患治療市場、タイプ別、2019～2032年
    • ラテンアメリカ：骨髄増殖性疾患治療市場、最終用途別、2019～2032年
    • ラテンアメリカ：骨髄増殖性疾患治療市場、治療別、2019～2032年
    • 骨髄増殖性疾患治療市場-メキシコ
    • 骨髄増殖性疾患治療市場-ブラジル
    • 骨髄増殖性疾患治療市場-アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • AbbVie
  • Bristol-Myers Squibb
  • Incyte Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Viatris（Mylan N.V.）
図表

List of Tables

  • Table 1 Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 2 Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 3 Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 4 Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 6 North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 7 North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 8 U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 10 U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 11 Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 13 Canada: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 14 Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 16 Europe: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 17 UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 18 UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 19 UK: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 20 France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 21 France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 22 France: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 23 Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 25 Germany: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 26 Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 28 Italy: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 29 Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 31 Spain: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 35 Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 37 Russia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 41 China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 42 China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 43 China: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 44 India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 45 India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 46 India: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 50 Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 52 Japan: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 56 South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 58 South Korea: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 65 UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 67 UAE: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 68 Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 70 Israel: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 71 South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 73 South Africa: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 74 Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 76 Latin America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 77 Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 79 Mexico: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 80 Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 82 Brazil: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • Table 83 Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • Table 85 Argentina: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Myeloproliferative Disorder Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment
  • Figure 7. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Type
  • Figure 9. Global Myeloproliferative Disorder Treatment Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by End-Use
  • Figure 11. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2022 & 2032 (USD Billion)
  • Figure 12. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Myeloproliferative Disorder Treatment Market
目次
Product Code: PM3936

The global myeloproliferative disorders treatment market size is expected to reach USD 13.13 billion by 2032, according to a new study by Polaris Market Research. The report "Myeloproliferative Disorder Treatment Market Share, Size, Trends, Industry Analysis Report, By Type (Polycythaemia Vera, Essential Thrombocythemia, Myelofibrosis, Other), By Treatment, By End-Use, By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

There is a growing availability of novel drugs and a strong pipeline of potential treatments. This has created optimism for more effective therapies in the future, driving interest and investment in the market. The rising incidence of myeloproliferative disorders can be attributed to changing lifestyles and an aging population. These factors have contributed to an increase in the number of individuals at risk of developing these conditions, leading to a higher demand for treatments.

Additionally, there is a heightened level of public awareness regarding myeloproliferative disorders. This increased awareness has led to earlier diagnosis and treatment, further fueling the demand for therapies in the market. Furthermore, the development of therapeutic options for patients who are intolerant to Jakafi, a commonly used medication for myeloproliferative disorders, is a notable trend. This second-line treatment approach addresses the needs of patients who may not respond well to Jakafi, expanding the market's potential patient base.

Chronic myeloproliferative disorders (MPDs) are a group of rare hematological malignancies characterized by the abnormal proliferation of certain types of blood cells in the bone marrow and peripheral blood. These disorders primarily affect the myeloid cell line, which includes red blood cells, granulocytes (a type of white blood cell), and platelets, as well as their precursor cells. These disorders are further categorized based on the presence or absence of the Philadelphia chromosome. The Philadelphia chromosome is a specific genetic abnormality resulting from a translocation (exchange of genetic material) between chromosomes 9 and 22. Its presence is a defining characteristic of CML.

Chronic myeloproliferative disorders are complex conditions that require careful diagnosis and management by healthcare professionals. Treatment options may include medications to control blood cell counts, manage symptoms, and reduce the risk of complications. In some cases, stem cell transplantation may be considered as a curative treatment option.

The higher incidence of myeloproliferative disorders (MPNs) in North America & Western Europe compared to East-Asian countries can be attributed to various factors, including differences in genetic predisposition, lifestyle, and environmental factors. While most MPN patients are diagnosed after the age of 60, these disorders can affect individuals of any age. The United States is poised to be the most prominent market for MPN drugs due to its substantial target population, advanced healthcare infrastructure, and significant investments in research and development, leading to the availability of innovative treatments for MPNs.

Myeloproliferative Disorders Treatment Market Report Highlights

  • The myelofibrosis segment held the largest share, owing to rising cases & increased research & development efforts to increase the efficacy of the treatment procedures
  • Chemotherapy segment led the market on account of a surge in cases of cancers due to changes in diet and busier lifestyle
  • North America garnered the largest share due to the presence of well-developed medical infrastructure, & huge industry-academia efforts for research & innovations
  • Key players include Novartis, Bristol-Myers, Incyte Corp, Takeda Pharmaceutical, Viatris, AbbVie, and Teva Pharmaceuticals

Polaris Market Research has segmented the myeloproliferative disorders treatment market report based on type, treatment, end-use, and region:

Myeloproliferative Disorders Treatment, Type Outlook (Revenue - USD Billion, 2023 - 2032)

  • Polycythaemia Vera
  • Essential Thrombocythemia
  • Myelofibrosis
  • Others

Myeloproliferative Disorders Treatment, Treatment Outlook (Revenue - USD Billion, 2023 - 2032)

  • Chemotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

Myeloproliferative Disorders Treatment, End-Use Outlook (Revenue - USD Billion, 2023 - 2032)

  • Hospitals
  • Specialty Clinics
  • Others

Myeloproliferative Disorders Treatment, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myeloproliferative Disorder Treatment Market Insights

  • 4.1. Myeloproliferative Disorder Treatment Market - End-Use Snapshot
  • 4.2. Myeloproliferative Disorder Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Growing demand for effective treatments
      • 4.2.1.2. Advancements in R&D and molecular understanding
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited treatment options
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Myeloproliferative Disorder Treatment Market End-Use Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myeloproliferative Disorder Treatment Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
  • 5.3. Polycythaemia Vera
    • 5.3.1. Global Myeloproliferative Disorder Treatment Market, by Polycythaemia Vera, by Region, 2019-2032 (USD Billion)
  • 5.4. Essential Thrombocythemia
    • 5.4.1. Global Myeloproliferative Disorder Treatment Market, by Essential Thrombocythemia, by Region, 2019-2032 (USD Billion)
  • 5.5. Myelofibrosis
    • 5.5.1. Global Myeloproliferative Disorder Treatment Market, by Myelofibrosis, by Region, 2019-2032 (USD Billion)
  • 5.6. Other
    • 5.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

6. Global Myeloproliferative Disorder Treatment Market, by Treatment

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Myeloproliferative Disorder Treatment Market, by Chemotherapy, by Region, 2019-2032 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Myeloproliferative Disorder Treatment Market, by Immunotherapy, by Region, 2019-2032 (USD Billion)
  • 6.5. Stem Cell Transplantation
    • 6.5.1. Global Myeloproliferative Disorder Treatment Market, by Stem Cell Transplantation, by Region, 2019-2032 (USD Billion)
  • 6.6. Other
    • 6.6.1. Global Myeloproliferative Disorder Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

7. Global Myeloproliferative Disorder Treatment Market, by End-Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Myeloproliferative Disorder Treatment Market, by Hospitals, By Region, 2019-2032 (USD Billion)
  • 7.4. Specialty Clinics
    • 7.4.1. Global Myeloproliferative Disorder Treatment Market, by Specialty Clinics, By Region, 2019-2032 (USD Billion)
  • 7.5. Other
    • 7.5.1. Global Myeloproliferative Disorder Treatment Market, by Other, By Region, 2019-2032 (USD Billion)

8. Global Myeloproliferative Disorder Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Myeloproliferative Disorder Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Myeloproliferative Disorder Treatment Market - North America
    • 8.3.1. North America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.3.3. North America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.4. Myeloproliferative Disorder Treatment Market - U.S.
      • 8.3.4.1. U.S.: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.3.5. Myeloproliferative Disorder Treatment Market - Canada
      • 8.3.5.1. Canada: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.4. Myeloproliferative Disorder Treatment Market - Europe
    • 8.4.1. Europe: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.4. Myeloproliferative Disorder Treatment Market - UK
      • 8.4.4.1. UK: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.5. Myeloproliferative Disorder Treatment Market - France
      • 8.4.5.1. France: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.6. Myeloproliferative Disorder Treatment Market - Germany
      • 8.4.6.1. Germany: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.7. Myeloproliferative Disorder Treatment Market - Italy
      • 8.4.7.1. Italy: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.8. Myeloproliferative Disorder Treatment Market - Spain
      • 8.4.8.1. Spain: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.9. Myeloproliferative Disorder Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.4.10. Myeloproliferative Disorder Treatment Market - Russia
      • 8.4.10.1. Russia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.5. Myeloproliferative Disorder Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.4. Myeloproliferative Disorder Treatment Market - China
      • 8.5.4.1. China: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.5. Myeloproliferative Disorder Treatment Market - India
      • 8.5.5.1. India: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.6. Myeloproliferative Disorder Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.7. Myeloproliferative Disorder Treatment Market - Japan
      • 8.5.7.1. Japan: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.8. Myeloproliferative Disorder Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.5.9. Myeloproliferative Disorder Treatment Market - South Korea
      • 8.5.9.1. South Korea: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.6. Myeloproliferative Disorder Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.4. Myeloproliferative Disorder Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.5. Myeloproliferative Disorder Treatment Market - UAE
      • 8.6.5.1. UAE: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.6. Myeloproliferative Disorder Treatment Market - Israel
      • 8.6.6.1. Israel: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.6.7. Myeloproliferative Disorder Treatment Market - South Africa
      • 8.6.7.1. South Africa: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
  • 8.7. Myeloproliferative Disorder Treatment Market - Latin America
    • 8.7.1. Latin America: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.4. Myeloproliferative Disorder Treatment Market - Mexico
      • 8.7.4.1. Mexico: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.5. Myeloproliferative Disorder Treatment Market - Brazil
      • 8.7.5.1. Brazil: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)
    • 8.7.6. Myeloproliferative Disorder Treatment Market - Argentina
      • 8.7.6.1. Argentina: Myeloproliferative Disorder Treatment Market, by Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Myeloproliferative Disorder Treatment Market, by End-Use, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Myeloproliferative Disorder Treatment Market, by Treatment, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Bristol-Myers Squibb
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Incyte Corporation
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Novartis AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Takeda Pharmaceutical Company Limited
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Teva Pharmaceuticals
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Viatris (Mylan N.V.)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development